IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Virtu Financial LLC

Virtu Financial LLC decreased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 66.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,300 shares of the medical research company’s stock after selling 10,274 shares during the period. Virtu Financial LLC’s holdings in IQVIA were worth $1,256,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of IQV. Capital Performance Advisors LLP acquired a new position in shares of IQVIA in the 3rd quarter valued at about $27,000. Park Place Capital Corp acquired a new position in IQVIA in the third quarter valued at approximately $28,000. Itau Unibanco Holding S.A. bought a new position in shares of IQVIA during the second quarter valued at approximately $29,000. International Assets Investment Management LLC acquired a new stake in shares of IQVIA during the 2nd quarter worth approximately $32,000. Finally, Avior Wealth Management LLC lifted its holdings in shares of IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Trading Down 0.3 %

Shares of IQVIA stock opened at $200.37 on Friday. The business has a fifty day simple moving average of $213.40 and a 200-day simple moving average of $224.61. The firm has a market cap of $36.37 billion, a price-to-earnings ratio of 26.30, a price-to-earnings-growth ratio of 2.07 and a beta of 1.49. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

Analysts Set New Price Targets

IQV has been the topic of several analyst reports. Barclays dropped their target price on IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Truist Financial dropped their price objective on shares of IQVIA from $265.00 to $261.00 and set a “buy” rating on the stock in a report on Thursday. The Goldman Sachs Group reduced their target price on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Leerink Partners restated an “outperform” rating and issued a $248.00 target price (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Finally, William Blair reiterated an “outperform” rating on shares of IQVIA in a research report on Wednesday. Four investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and a consensus target price of $257.60.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.